Pyridostigmine in Pediatric Intestinal Pseudo-obstruction: Case Report of a 2-year Old Girl and Literature Review.
Cholinesterase inhibitors
Enteric nervous system
Gastrointestinal motility
Intestinal pseudo-obstruction
Pyridostigmine bromide
Journal
Journal of neurogastroenterology and motility
ISSN: 2093-0879
Titre abrégé: J Neurogastroenterol Motil
Pays: Korea (South)
ID NLM: 101530189
Informations de publication
Date de publication:
30 10 2019
30 10 2019
Historique:
received:
08
04
2019
revised:
04
06
2019
accepted:
20
07
2019
entrez:
8
10
2019
pubmed:
8
10
2019
medline:
8
10
2019
Statut:
ppublish
Résumé
Pediatric chronic intestinal pseudo-obstruction is a rare disorder characterized by a severe impairment of gastrointestinal motility leading to intestinal obstruction symptoms in the absence of mechanical causes. The diagnosis is usually clinical and diagnostic work is usually aimed to rule out mechanical obstruction and to identify any underlying diseases. Treatment is challenging and requires a multidisciplinary effort. In this manuscript we describe the youngest child successfully treated with the orally administrable, longacting, reversible anti-cholinesterase drug, pyridostigmine. Like other drugs belonging to cholinesterase inhibitors, pyridostigmine enhances gut motility by increasing acetylcholine availability in the enteric nervous system and neuro-muscular junctions. Based on the direct evidence from the reported case, we reviewed the current literature on the use of pyridostigmine in severe pediatric dysmotility focusing on intestinal pseudo-obstruction. The overall data emerged from the few published studies suggest that pyridostigmine is an effective and usually well tolerated therapeutic options for patients with intestinal pseudo-obstruction. More specifically, the main results obtained by pyridostigmine included marked reduction of abdominal distension, reduced need of parenteral nutrition, and improvement of oral feeding. The present case and review on pyridostigmine pave the way for eagerly awaited future randomized controlled studies testing the efficacy of cholinesterase inhibitors in pediatric severe gut dysmotility.
Identifiants
pubmed: 31587541
pii: jnm19078
doi: 10.5056/jnm19078
pmc: PMC6786444
doi:
Types de publication
Review
Langues
eng
Pagination
508-514Références
Clin Gastroenterol Hepatol. 2005 May;3(5):449-58
pubmed: 15880314
J Clin Pharmacol. 1998 Mar;38(3):227-35
pubmed: 9549661
J Pediatr Gastroenterol Nutr. 2018 Jun;66(6):991-1019
pubmed: 29570554
Ann Med Surg (Lond). 2014 Jun 19;3(3):60-4
pubmed: 25568788
Gastroenterology. 1961 Jan;40:18-26
pubmed: 13692638
Turk J Pediatr. 2009 Mar-Apr;51(2):195-8
pubmed: 19480337
Clin Pharmacokinet. 1986 May-Jun;11(3):236-49
pubmed: 3524957
Clin Nutr. 2018 Aug;37(4):1415-1422
pubmed: 28701261
Eur J Clin Pharmacol. 1979 Jun 12;15(5):367-71
pubmed: 456409
Fundam Appl Toxicol. 1990 Jan;14(1):40-53
pubmed: 2307321
Alzheimer Dis Assoc Disord. 2000 Oct-Dec;14(4):216-27
pubmed: 11186600
Br J Clin Pharmacol. 1998 Nov;46 Suppl 1:1-6
pubmed: 9839758
Korean J Hematol. 2010 Mar;45(1):62-5
pubmed: 21120165
Neurogastroenterol Motil. 2017 Jan;29(1):null
pubmed: 27683196
Br J Pharmacol. 1979 Aug;66(4):525-30
pubmed: 223706
Clin Drug Investig. 2011 Oct 1;31(10):691-701
pubmed: 21815707
Am J Physiol Gastrointest Liver Physiol. 2001 Nov;281(5):G1228-37
pubmed: 11668032
Pediatrics. 2018 Apr;141(Suppl 5):S404-S407
pubmed: 29610160
J Pediatr Gastroenterol Nutr. 2019 Jan;68(1):e16-e17
pubmed: 30334933
Paediatr Drugs. 2018 Apr;20(2):173-180
pubmed: 29243034
Fortschr Neurol Psychiatr. 1996 Mar;64(3):110-21
pubmed: 8900891
Colorectal Dis. 2010 Jun;12(6):540-8
pubmed: 19508545
Exp Neurol. 2003 Feb;179(2):181-7
pubmed: 12618125
Am J Physiol. 1990 Apr;258(4 Pt 2):R951-7
pubmed: 2184685
J Pediatr Surg. 2002 Oct;37(10):E28
pubmed: 12378474